CureVac presents new, updated data at mRNA Health Conference

CureVac (CVAC) announced that new and updated data will be shared in two oral presentations and four posters at the 12th International mRNA Health Conference, taking place in Boston, Massachusetts, November 12-14, 2024. More detailed preliminary safety, tolerability and immunogenicity data from the dose escalation part of CureVac’s ongoing Phase 1 CVGBM cancer vaccine study in patients with resected glioblastoma will be shared in an oral presentation. Initial data from this study was presented last month at the European Society for Medical Oncology Congress demonstrating that treatment with CVGBM monotherapy successfully induced cancer antigen-specific T-cell responses in 77% of evaluable patients, of which 84% of immune responses were generated de novo by the vaccine.Expanded data from the dose escalation portion of the study will also be shared at the upcoming Society for Immunotherapy of Cancer 39th Annual Meeting later this week. A second oral presentation will cover CureVac’s approach to developing optimized LNP delivery, while posters shared at the meeting will provide additional data on how CureVac optimizes its mRNA platform with different approaches as well as highlighting new targets for future development programs. The data to be shared will demonstrate the potential of CureVac’s mRNA platform in technology optimization, oncology, and infectious disease, driving future innovation in the mRNA space. “With our recent corporate realignment and increased focus on research and innovation to develop meaningful mRNA medicines in different therapeutic areas, CureVac is more committed than ever to extending the horizons of mRNA. We are pleased to be presenting the recently announced promising clinical data from our glioblastoma mRNA vaccine program as well as results from our ongoing research in lipid nanoparticle delivery technology, oncology and infectious diseases,” said Dr. Myriam Mendila, Chief Scientific Officer at CureVac. “These presentations demonstrate the evolution of our long-standing commitment to apply mRNA technology in service to patients across a diverse spectrum of disease areas.”